Clinical Observation Of Ruogan Granule Combined With Entecavir In The Treatment Of Compensatory Hepatitis B Cirrhosis(Liver Depression And Spleen Deficiency Combined With Blood Stasis Syndrome)

Objective:This study is mainly to observe the clinical efficacy of Ruogan Granule combined with Entecavir in the treatment of the compensatory stage of liver function of posthepatitis B cirrhosis(liver depression and spleen deficiency combined with blood stasis syndrome),and to explore the advantages of integrated Chinese and Western medicine in the treatment of this disease,so as to provide scientific and effective treatment ideas and clinical basis for the treatment of this disease.Methods:Sixty patients in the outpatient department of liver,spleen and stomach of the First Affiliated Hospital of Heilongjiang University of Chinese Medicine from March 2022 to February 2023 who met the inclusion criteria of this study were selected and divided into experimental group and control group by random number table method at 1:1,with 30 patients in each group.The control group was given oral Entecavir tablet treatment,and the experimental group was additionally treated with Ruogan Granules on the basis of the control group.Both groups were treated for 12 weeks.TCM syndrome score,HBV-DNA quantitative value,liver function index(ALT,AST,Alb,TBil),coagulation function(PT,APTT,TT,FIB),four items of liver fibrosis(IV-C,HA,PC-Ⅲ,LN)and abdominal color Doppler scores were recorded in the two groups before and after treatment.SPSS26.0statistical software was used for further statistics and analysis of all data,so as to compare the differences in clinical efficacy between the two groups.Results:1.Comparison of TCM syndrome scores: After treatment,TCM single symptom scores and total TCM syndrome scores of the two groups were decreased(P<0.05),and the experimental group was better than the control group(P<0.05).2.Comparison of the curative effect of TCM syndrome: After treatment,the total effective rate of the experimental group was 86.21%,and that of the control group was 68.97%,and the experimental group was better than the control group(P<0.05).3.Comparison of HBV-DNA quantitative values: After treatment,the quantitative values of HBV-DNA in both groups were decreased(P<0.05),and the experimental group was better than the control group(P<0.05).4.Liver function indexes: After treatment,the values of ALT,AST and TBIL in serum of two groups were decreased(P<0.05),while the content of ALB was increased(P<0.05),and the experimental group was better than the control group(P<0.05).5.Index of coagulation function: After treatment,PT,APTT and TT values of both groups were decreased(P<0.05),while FIB values was increased(P<0.05),and the experimental group was better than the control group(P<0.05).6.Four items of liver fibrosis: After treatment,the values of HA,LN,PC-Ⅲ and IV-C in two groups were decreased(P<0.05),and the experimental group was better than the control group(P<0.05).7.Abdominal color doppler ultrasound score: After treatment,abdominal color doppler ultrasound score were decreased in both groups(P<0.05),and experimental group was better than control group(P<0.05).8.Overall efficacy: The total effective rate of the experimental group was89.66%,and the total effective rate of the control group was 68.97%.Compared with the two groups,the overall efficacy of the experimental group was better than the control group(P<0.05).Conclusions:1.Ruogan Granule combined with Entecavir can effectively improve the clinical syndrome of traditional Chinese medicine in patients with liver depression and spleen deficiency combined with blood stasis syndrome in the compensatory stage of liver function of posthepatitis B cirrhosis,and the efficacy is better than entecavir alone.2.Ruogan Granule combined with Entecavir can effectively inhibit HBV replication,improve liver function,coagulation function,liver fibrosis degree,and reduce abdominal color ultrasound scores in the treatment of patients with liver depression and spleen deficiency combined with blood stasis syndrome in the compensatory stage of liver function of posthepatitis B cirrhosis,and the efficacy is better than entecavir alone.